Skip to main content

Advertisement

SpringerLink
Log in

Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The aim of the study was to determine the concentration of pneumococcal antibodies after a dose of 7-valent pneumococcal conjugate vaccine (PCV7) in 30 asplenic children between 4 months and 19 years of age. Fifteen children had received pneumococcal polysaccharide vaccine (PPV) approximately 5 years prior to vaccination with PCV7. The antibody concentrations against serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F were measured by ELISA before and after the PCV7 vaccination. Before vaccination with PCV7, the antibody concentrations were similar in children who had or had not received PPV previously. A dose of PCV7 stimulated a good immune response in asplenic patients. Prior immunization with PPV did not affect the antibody concentration after the vaccination with PCV7. In conclusion, asplenic children vaccinated with PPV may need revaccination with PPV earlier than the recommended 3–5 years after the first dose. PCV7 induces a satisfactory immune response in asplenic patients and should be considered as an alternative vaccine in that patient group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dickerman JD (1979) Splenectomy and sepsis: a warning. Pediatrics 63:938–941

    PubMed  CAS  Google Scholar 

  2. Singers DB (1973) Postsplenectomy sepsis. Perspect Pediatr Pathol 1:285–311

    Google Scholar 

  3. Lynch AM, Kapila R (1996) Overwhelming postsplenectomy infection. Infect Dis Clin North Am 10:693–707

    Article  PubMed  CAS  Google Scholar 

  4. Sumaraju V, Leon G, Smith SM (2001) Infectious complications in asplenic hosts. Infect Dis Clin North Am 15:551–565

    Article  PubMed  CAS  Google Scholar 

  5. Hausdorff WP, Bryant J, Paradiso PR, Siber GR (2000) Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use. I. Clin Infect Dis 30:100–121

    Article  PubMed  CAS  Google Scholar 

  6. Schutze GE, Mason EO, Barson WJ et al (2002) Invasive pneumococcal infections in children with asplenia. Pediatr Infect Dis J 21:278–282

    Article  PubMed  Google Scholar 

  7. Lutwick LI (2000) Infections in asplenic patients. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious disease. Churchill Livingstone, Philadelphia, pp 3169–3176

    Google Scholar 

  8. Davidson RN, Wall RA (2001) Prevention and management of infection in patients without a spleen. Clin Microbiol Infect 7:657–666

    Article  PubMed  CAS  Google Scholar 

  9. American Academy of Pediatrics (2006) Immunocompromised children—asplenic children. The Red Book on CD-ROM, Report of the Committee on Infectious Disease, 27th edn. American Academy of Pediatrics, Elk Grove Village

    Google Scholar 

  10. Melles DC, de Marie S (2004) Prevention of infections in hyposplenic and asplenic patients: an update. Neth J Med 62(2):45–52

    PubMed  CAS  Google Scholar 

  11. Cullingford GL, Watkins DN, Watt AD, Mallon DF (1991) Severe late postsplenectomy infection. Br J Surg 78:716–721

    Article  PubMed  CAS  Google Scholar 

  12. Williams DN, Kaur B (1996) Postsplenectomy care. Strategies to decrease the risk of infection. Postgrad Med 100(1):195–198

    Article  PubMed  CAS  Google Scholar 

  13. Brigden ML (2001) Detection, education and management of the asplenic or hyposplenic patient. Am Family Physician 63(3):499–506

    CAS  Google Scholar 

  14. Castagnola E, Fioredda F (2003) Prevention of life-threatening infections due to encapsula bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes. Eur J Haematol 71:319–326

    Article  PubMed  Google Scholar 

  15. ACIP (2000) Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49(RR-9):1–35

    Google Scholar 

  16. Canadian Pediatrics Society (1999) Prevention and therapy of bacterial infections for children with asplenia or hyposplenia. Paediatr Child Health 4(6):417–421

    Google Scholar 

  17. World Health Organization (2005) Recommendations for the production and control of pneumococcal conjugate vaccines. World Health Organ Tech Rep Se 927(Annex 2):64–98

    Google Scholar 

  18. Black S, Shinefield H, Fireman B et al (2000) Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Am J Manag Care 6 [10 Suppl]:536–549

    Google Scholar 

  19. Pedersen FK, Nielsen JL, Ellegaard J (1982) Antibody response to pneumococcal vaccine in splenectomized adults and adolescents. Acta Pathol Microbiol Immunol Scand 90:257–263

    CAS  Google Scholar 

  20. Giebnik GS, Le CT, Cosio FG et al (1981) Serum antibody responses of high-risk children and adults to vaccination with capsular polysaccharides of Streptococcus pneumoniae. Rev Infect Dis 3 [Suppl]:168–178

    Google Scholar 

  21. Sullivan JL, Ochs HD, Schiffman G et al (1978) Immune response after splenectomy. Lancet 1(8057):178–181

    Article  PubMed  CAS  Google Scholar 

  22. Caplan ES, Boltansky H, Schnyder MJ et al (1983) Response of traumatized splenectomized patients to immediate vaccination with polyvalent pneumococcal vaccine. J Trauma 23(9):801–805

    PubMed  CAS  Google Scholar 

  23. Siber GR (1997) Methods for estimating serologic correlates of protection. Dev Biol Stand 89:283–296

    PubMed  CAS  Google Scholar 

  24. Robbins JB, Austrian R, Lee CJ et al (1983) Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 148:1136–1159

    PubMed  CAS  Google Scholar 

  25. Sleeman K, Knox K, George R et al (2001) Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis 183:239–246

    Article  PubMed  CAS  Google Scholar 

  26. Shurin PA, Rehmus JM, Johnson CE et al (1993) Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high risk children. J Pediatr 123:801–810

    Article  PubMed  CAS  Google Scholar 

  27. Jugenburg M, Haddock G, Freedman MH et al (1999) The morbidity and mortality of pediatric post splenectomy: does prophylaxis make a difference? J Pediatr Surg 34(7):1064–1067

    Article  PubMed  CAS  Google Scholar 

  28. Skoczynska A, Hryniewicz W (2003) Genetic relatedness, antibiotic susceptibility, and serotype distribution of Streptococcus pneumoniae responsible for meningitis in Poland, 1997–2001. Microb Drug Resist 9(2):175–182

    Article  PubMed  CAS  Google Scholar 

  29. Finn A, Booy R, Moxon R et al (2002) Should the new pneumococcal vaccine be used in high-risk children? Arch Dis Child 87:18–21

    Article  PubMed  CAS  Google Scholar 

  30. Sulikowska A, Grzesiowski P, Sadowy E et al (2004) Characteristics of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated from the nasopharynges of asymptomatic children and molecular analysis of S. pneumoniae and H. influenzae strain replacement in the nasopharynx. J Clin Microbiol 42(9):3942–3949

    Article  PubMed  CAS  Google Scholar 

  31. American Academy of Pediatrics (2000) Committee on infectious diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevenar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 106(2):362–366

    Article  Google Scholar 

  32. Nachman S, Kim S, King J, Abrams EJ et al (2003) Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 112(1):66

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Bozena Kusmirek for her laboratory support. We thank Raili Haikala, Sinikka Grönholm, and Anne Holm for performing the pneumococcal antibody determinations.

The investigation was supported by a grant from the Polish Ministry of Science: NN402243033, EU grant EURO-POLICY-PID SP23-CT-2005–006411, and the Children’s Memorial Health Institute grant 71/05.

Author information

Authors and Affiliations

  1. Department of Pediatrics and Developmental Disorders of Children and Adolescents, Medical University in Bialystok, 17 Waszyngtona Street, 15–224, Bialystok, Poland

    B. Mikoluc & R. Motkowski

  2. Department of Vaccines, National Public Health Institute, Mannerheimintie 166, Helsinki, Finland

    H. Kayhty

  3. Department of Immunology, The Children’s Memorial Health Institute, 20 Dzieci Polskich Av., 04–736, Warsaw, Poland

    E. Bernatowska

Authors
  1. B. Mikoluc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Kayhty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Bernatowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Motkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Mikoluc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mikoluc, B., Kayhty, H., Bernatowska, E. et al. Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children. Eur J Clin Microbiol Infect Dis 27, 923–928 (2008). https://doi.org/10.1007/s10096-008-0523-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-008-0523-5

Keywords

Search

Navigation